A drug designed to lower the huntingtin protein without a lumbar puncture or brain surgery has entered first-in-human testing. The registration for the INSIGHTT study (NCT07536061), sponsored by Sarepta Therapeutics, records an actual start date of 12 May 2026 and lists the trial as recruiting, with an estimated 32 participants across four ascending-dose cohorts. The design is randomised, placebo-controlled and triple-masked (participant, care provider and investigator), and the study drug, SRP-1005 (formerly ARO-HTT), is given by subcutaneous injection. Two sites are listed, both in New Zealand: the New Zealand Brain Research Institute in Christchurch, where Timothy Anderson is principal investigator and recruitment is open, and Pacific Clinical Research Network in Auckland, where Richard Roxburgh is principal investigator and the site is listed as not yet recruiting. Sarepta said on 5 August 2026 that dosing in INSIGHTT was underway.

Eligibility is narrow. The registry requires a genetically confirmed HTT CAG repeat length of 40 or more and classification as Stage 2 or mild Stage 3 on the HD Integrated Staging System, assessed at screening with the Enroll-HD modified calculator, which limits enrolment to people with established but not advanced disease. The single primary outcome is the number of participants with treatment-emergent adverse events, serious adverse events and adverse events of special interest, measured from baseline through Week 24. The three registered secondary outcomes are all drug levels: concentrations of SRP-1005 in plasma and urine through Day 17, and in cerebrospinal fluid through Week 24. Primary completion is estimated for 30 November 2027. The record lists no data monitoring committee and states that the drug is not FDA-regulated in this study, consistent with a trial run outside the United States.

The route is the reason the programme is being watched. Sarepta describes SRP-1005 as an siRNA carried into the central nervous system by a monovalent antigen-binding fragment aimed at transferrin receptor 1, with subcutaneous dosing intended to keep exposure below receptor saturation while maintaining penetration across the blood brain barrier. The company said its preclinical work showed the potential for protein knockdown in the putamen and caudate and in the temporal and frontal cortex; that is laboratory and animal evidence, and it has not been shown in people. Medsafe, New Zealand's Medicines and Medical Devices Safety Authority, approved the clinical trial application on 4 February 2026, five weeks after Sarepta said it had filed.

Two details temper the story. The company's own announcements described a study of approximately 24 participants, while the registry now gives an estimated enrolment of 32, and neither number is large. More importantly, no measure of huntingtin lowering appears among the registered primary or secondary outcomes: the trial asks whether the injections are tolerated and where the drug goes, not yet whether the target protein falls or whether anyone does better. Cerebrospinal fluid concentration of a drug is a measure of exposure, not of effect.